Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis Source: Eur Respir J 2017; 49(1): 1600993; DOI: 10.1183/13993003.00993-2016 Year: 2017
Outcomes for multidrug-resistant tuberculosis patients with and without resistance to fluoroquinolones and second-line injectable drugs: A meta-analysis of individual patient data Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012
Comparing cost-effectiveness of standardised tuberculosis treatments given varying drug resistance Source: Eur Respir J 2014; 43: 566-581 Year: 2013
Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis Source: Eur Respir J 2013; 42: 169-179 Year: 2013
Results of traditional and new regimens of MDR/XDR TB treatment: cohort analysis Source: International Congress 2019 – Drug-resistant tuberculosis Year: 2019
Safety and tolerability to long term moxifloxacin treatment in 38 patients with difficult to manage tuberculosis: preliminary data Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004
Evaluation of efficacy and safety of linezolid for the treatment of drug-resistant tuberculosis: case series report of 12 patients Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009
Getting the best possible evidence from observational studies of treatment of multidrug-resistant tuberculosis patients Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Cost-effectiveness of antibiotics for COPD management: observational analysis using CPRD data Source: ERJ Open Res, 3 (2) 00085-2016; 10.1183/23120541.00085-2016 Year: 2017
The effectiveness of the introduction of the updated treatment regimens and microbiological diagnostics MDR/XDR tuberculosis Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019
Cost impact of time to initiation of triple therapy in COPD patients in Japan: A retrospective analysis of healthcare claims data Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017
Multicentre randomised clinic study of new standard chemotherapy regimen for new cases patients of pulmonary tuberculosis executed in Russia regions with high level of multiple drug resistance (MDR) Source: Annual Congress 2009 - Tuberculosis control Year: 2009
Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis Source: Eur Respir J 2012; 40: 1430-1442 Year: 2012
Evaluation of prophylactic observations efficacy and the quality of TB treatment using a math model for primarily revealed patients Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004
Frequency of drug resistance and treatment results with standard chemotherapeutical regimen in patients with newly detected tuberculosis on the data of district hospital, Kiev Source: Eur Respir J 2002; 20: Suppl. 38, 548s Year: 2002
Frequency of drug resistance and treatment results in patients with newly detected tuberculosis using standard chemotherapeutical regimen on the data of district hospital, Kiev Source: Eur Respir J 2002; 20: Suppl. 38, 402s Year: 2002
The effectiveness and safety of empirical anti-TB therapy in a population with high TB prevalence Source: Eur Respir J 2001; 18: Suppl. 33, 468s Year: 2001
Evaluation of the efficacy and safety of moxifloxacin in the treatment of drug-resistant pulmonary tuberculosis; a clinical trial Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008
Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis Source: Eur Respir J, 55 (3) 1901467; 10.1183/13993003.01467-2019 Year: 2020
Short 12-month regimen with intravenouse linezolid for MDR-TB: treatment outcomes and first follow up results. Source: International Congress 2018 – New developments in tuberculosis Year: 2018